Oclacitinib is a potent, safe and rapidly acting anti-itching JAK inhibitor. Oclacitinib was first approved by the US FDA in 2013 to treat eczema and allergic dermatitis in dogs, it is a first generation non-selective JAK inhibitor. The treatment protocol is 0.4 to 0.6 mg/kg administered orally twice a day for 2 weeks, followed by […]
Roflumilast and Tapinarof; Emerging Therapies for Atopic Dermatitis
Roflumilast and Tapinarof are 2 emerging topical therapies that have completed or have ongoing phase 3 clinical trials, with the possibility of approval in 2022. Roflumilast is a more potent PDE4 inhibitor than crisaborloe (Eucrisa) with fewer local reactions. Tapinarof, the first therapeutic arylhydocarbon modulating agent for which the only associated local effect is noninfectious […]
Asivatrep a new topical treatment for Eczema
Asivatrep is a new potential treatment for eczema (atopic dermatitis). Atopic dermatitis is a chronic inflammatory itchy skin disease that affects up to 25% of children and 10% of adults. The cause is complex and multifactorial. Currently there are few classes of topical medications to treat it. Steroids Calcineurin inhibitors (Elidel, Protopic) Phosphodiesterase 4 inhibitors Eucrisa […]
Opzelura (ruxolitinib) for Eczema
Opzelura (ruxolitinib) has been FDA approved for eczema. Opzelura is a topical JAK inhibitor, and its indicated for short term use in patients 12 and up who have mild to moderate atopic dermatitis. It is the first topical janus kinase inhibitor approved in the United States. Currently for atopic dermatitis topical treatment, the mainstay of […]
Upadacitinib for Atopic Dermatitis (Eczema)
Upadacitinib is an oral JAK1 inhibitor being developed for patients with severe atopic dermatitis. Multiple phase 2 randomized placebo controlled studies have examined the efficacy of upadacitinib in adults and adolescent patients with moderate to severe atopic dermatitis. Published in The Lancet, 2 replicate 16-week trials showed that monotherapy with upadacitinib improved symptom and disease severity compared […]
Eczema and Dementia Risk
Past studies have suggested that there is a link between eczema and dementia. Patients with dementia have a higher prevalence of eczema than those without. According the the World Health Organization, eczema (atopic dermatitis) is 15th among all nonfatal diseases and is the largest disease burden among all skin diseases. Eczema peaks in early childhood, […]
Abrocitinib vs. Dupilumab for Atopic Dermatitis
Abrocitinib vs. Dupilumab will be an important question for many prescribing doctors with the expected FDA approval of abrocitinib soon. We have extensively discussed atopic dermatitis (eczema) in the past. For many years only topical therapies were available for this condition. Topical steroids are the mainstays of treatment, and after many years newer topical therapies […]
Baricitinib for Atopic Dermatitis (Eczema)
Baricitinib is currently being studied for the treatment of atopic dermatitis. Baricitinib is part of the family of oral Janus kinase inhibitors that are an emerging modality in the treatment of chronic allergic inflammatory disorders due to their ability to inhibit signaling of multiple pathways of cytokines. We discussed in another blog post, Abrocitinib which is […]
Omalizumab for Atopic Dermatitis
Omalizumab for atopic dermatitis has shown promising results. In JAMA Pediatrics, the researchers have demonstrated for the first time that omalizumab, which neutralizes IgE, reduced disease severity and improved quality of life in pediatric patients with severe atopic dermatitis. This was the case even in subjects with very high baseline total plasma IgE levels. Omaizumab […]
Ruxolitinib for Eczema (atopic dermatitis)
Ruxolitinib is a new medication being studied for the treat of eczema. Ruxolitinib is a selective inhibitor of Janus kinase 1 and Janus kinase 2, it potently suppresses cytokine signaling involved in atopic dermatitis pathogenesis. We discussed the Janus Kinase pathway in a previous post and how new drugs are being developed for the treatment […]